Early studies of Merck & Co’s experimental oral COVID-19 antiviral drug, molnupiravir, show the pill to be effective against known variants of the coronavirus. The investigational medicine significantly reduced the risk of hospitalization or death in the trials. At the interim analysis, the antiviral reduced the risk of hospitalization or death by approximately 50%.